1
|
Boer J, Young-Sciame R, Lee F, Bowman KJ, Yang X, Shi JG, Nedza FM, Frietze W, Galya L, Combs AP, Yeleswaram S, Diamond S. Roles of UGT, P450, and Gut Microbiota in the Metabolism of Epacadostat in Humans. Drug Metab Dispos 2016; 44:1668-74. [DOI: 10.1124/dmd.116.070680] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2016] [Accepted: 07/20/2016] [Indexed: 12/21/2022] Open
|
2
|
Xue CB, Chen L, Cao G, Zhang K, Wang A, Meloni D, Glenn J, Anand R, Xia M, Kong L, Huang T, Feng H, Zheng C, Li M, Galya L, Zhou J, Shin N, Baribaud F, Solomon K, Scherle P, Zhao B, Diamond S, Emm T, Keller D, Contel N, Yeleswaram S, Vaddi K, Hollis G, Newton R, Friedman S, Metcalf B. Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 Activity. ACS Med Chem Lett 2010; 1:483-7. [PMID: 24900235 DOI: 10.1021/ml1001536] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2010] [Accepted: 08/23/2010] [Indexed: 11/28/2022] Open
Abstract
To identify a CCR5 antagonist as an HIV-1 entry inhibitor, we designed a novel series of indane derivatives based on conformational considerations. Modification on the indane ring led to the discovery of compound 22a (INCB9471) that exhibited high affinity for CCR5, potent anti-HIV-1 activity, high receptor selectivity, excellent oral bioavailability, and a tolerated safety profile. INCB9471 has entered human clinical trials.
Collapse
Affiliation(s)
- Chu-Biao Xue
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Lihua Chen
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Ganfeng Cao
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Ke Zhang
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Anlai Wang
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - David Meloni
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Joseph Glenn
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Rajan Anand
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Michael Xia
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Ling Kong
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Taisheng Huang
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Hao Feng
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Changsheng Zheng
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Mei Li
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Laurine Galya
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Jiacheng Zhou
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Niu Shin
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Fredric Baribaud
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Kim Solomon
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Peggy Scherle
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Bitao Zhao
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Sharon Diamond
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Tom Emm
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Douglas Keller
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Nancy Contel
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Swamy Yeleswaram
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Kris Vaddi
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Gregory Hollis
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Robert Newton
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Steven Friedman
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| | - Brian Metcalf
- Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880
| |
Collapse
|
3
|
Lin Q, Meloni D, Pan Y, Xia M, Rodgers J, Shepard S, Li M, Galya L, Metcalf B, Yue TY, Liu P, Zhou J. Enantioselective Synthesis of Janus Kinase Inhibitor INCB018424 via an Organocatalytic Aza-Michael Reaction. Org Lett 2009; 11:1999-2002. [DOI: 10.1021/ol900350k] [Citation(s) in RCA: 124] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Qiyan Lin
- Incyte Corporation, Experimental Station, Route 141 and Henry Clay Road, Wilmington, Delaware 19880
| | - David Meloni
- Incyte Corporation, Experimental Station, Route 141 and Henry Clay Road, Wilmington, Delaware 19880
| | - Yongchun Pan
- Incyte Corporation, Experimental Station, Route 141 and Henry Clay Road, Wilmington, Delaware 19880
| | - Michael Xia
- Incyte Corporation, Experimental Station, Route 141 and Henry Clay Road, Wilmington, Delaware 19880
| | - James Rodgers
- Incyte Corporation, Experimental Station, Route 141 and Henry Clay Road, Wilmington, Delaware 19880
| | - Stacey Shepard
- Incyte Corporation, Experimental Station, Route 141 and Henry Clay Road, Wilmington, Delaware 19880
| | - Mei Li
- Incyte Corporation, Experimental Station, Route 141 and Henry Clay Road, Wilmington, Delaware 19880
| | - Laurine Galya
- Incyte Corporation, Experimental Station, Route 141 and Henry Clay Road, Wilmington, Delaware 19880
| | - Brian Metcalf
- Incyte Corporation, Experimental Station, Route 141 and Henry Clay Road, Wilmington, Delaware 19880
| | - Tai-Yuen Yue
- Incyte Corporation, Experimental Station, Route 141 and Henry Clay Road, Wilmington, Delaware 19880
| | - Pingli Liu
- Incyte Corporation, Experimental Station, Route 141 and Henry Clay Road, Wilmington, Delaware 19880
| | - Jiacheng Zhou
- Incyte Corporation, Experimental Station, Route 141 and Henry Clay Road, Wilmington, Delaware 19880
| |
Collapse
|
4
|
Combs AP, Yue EW, Bower M, Ala PJ, Wayland B, Douty B, Takvorian A, Polam P, Wasserman Z, Zhu W, Crawley ML, Pruitt J, Sparks R, Glass B, Modi D, McLaughlin E, Bostrom L, Li M, Galya L, Blom K, Hillman M, Gonneville L, Reid BG, Wei M, Becker-Pasha M, Klabe R, Huber R, Li Y, Hollis G, Burn TC, Wynn R, Liu P, Metcalf B. Structure-Based Design and Discovery of Protein Tyrosine Phosphatase Inhibitors Incorporating Novel Isothiazolidinone Heterocyclic Phosphotyrosine Mimetics. J Med Chem 2005; 48:6544-8. [PMID: 16220970 DOI: 10.1021/jm0504555] [Citation(s) in RCA: 83] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Structure-based design led to the discovery of novel (S)-isothiazolidinone ((S)-IZD) heterocyclic phosphotyrosine (pTyr) mimetics that when incorporated into dipeptides are exceptionally potent, competitive, and reversible inhibitors of protein tyrosine phosphatase 1B (PTP1B). The crystal structure of PTP1B in complex with our most potent inhibitor 12 revealed that the (S)-IZD heterocycle interacts extensively with the phosphate binding loop precisely as designed in silico. Our data provide strong evidence that the (S)-IZD is the most potent pTyr mimetic reported to date.
Collapse
Affiliation(s)
- Andrew P Combs
- Discovery Chemistry, Incyte Corporation, Experimental Station, E336/132A, Route 141 and Henry Clay Road, Wilmington, DE 19880, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|